Outputs (6)

Antiplatelet therapy with aspirin, clopidogrel, and dipyridamole versus clopidogrel alone or aspirin and dipyridamole in patients with acute cerebral ischaemia (TARDIS): a randomised, open-label, phase 3 superiority trial (2017)
Journal Article
Bath, P. M., Christensen, L. M., Woodhouse, L. J., Bentsen, L., Appleton, J. P., Krarup Hansen, C., Beridze, M., Thomsen, T. T., Christensen, H., Kruuse, C., Dineen, R. A., Jensen, H. H., Duley, L., Hansen, S. S., England, T. J., Petrovic, V., Flaherty, K., Beridze, N., Havard, D., Kakabadze, N., …Farren, P. (2018). Antiplatelet therapy with aspirin, clopidogrel, and dipyridamole versus clopidogrel alone or aspirin and dipyridamole in patients with acute cerebral ischaemia (TARDIS): a randomised, open-label, phase 3 superiority trial. Lancet, 391(10123), 850-859. https://doi.org/10.1016/S0140-6736%2817%2932849-0

Background: Intensive antiplatelet therapy with three agents might be more effective than guideline treatment for preventing recurrent events in patients with acute cerebral ischaemia. We aimed to compare the safety and efficacy of intensive antiplat... Read More about Antiplatelet therapy with aspirin, clopidogrel, and dipyridamole versus clopidogrel alone or aspirin and dipyridamole in patients with acute cerebral ischaemia (TARDIS): a randomised, open-label, phase 3 superiority trial.

NAD-biosynthetic enzyme NMNAT1 reduces early behavioral impairment in the htau mouse model of tauopathy (2017)
Journal Article
Rossi, F., Geiszler, P. C., Meng, W., Barron, M., Prior, M., Herd-Smith, A., …Conforti, L. (2018). NAD-biosynthetic enzyme NMNAT1 reduces early behavioral impairment in the htau mouse model of tauopathy. Behavioural Brain Research, 339, https://doi.org/10.1016/j.bbr.2017.11.030

NAD metabolism and the NAD biosynthetic enzymes nicotinamide nucleotide adenylyltransferases (NMNATs) are thought to play a key neuroprotective role in tauopathies, including Alzheimer’s disease. Here, we investigated whether modulating the expressio... Read More about NAD-biosynthetic enzyme NMNAT1 reduces early behavioral impairment in the htau mouse model of tauopathy.

Brain activation in response to personalized behavioral and physiological feedback from self-monitoring technology: pilot study (2017)
Journal Article
Whelan, M. E., Morgan, P. S., Sherar, L. B., Kingsnorth, A. P., Magistro, D., & Esliger, D. W. (2017). Brain activation in response to personalized behavioral and physiological feedback from self-monitoring technology: pilot study. Journal of Medical Internet Research, 19(11), Article e384. https://doi.org/10.2196/jmir.8890

Background: The recent surge in commercially available wearable technology has allowed real-time self-monitoring of behaviour (eg, physical activity) and physiology (eg, glucose levels). However, there is limited neuroimaging work (ie, functional mag... Read More about Brain activation in response to personalized behavioral and physiological feedback from self-monitoring technology: pilot study.

Subthalamic deep brain stimulation sweet spots and hyperdirect cortical connectivity in Parkinson’s disease (2017)
Journal Article
Akram, H., Sotiropoulos, S. N., Jbabdi, S., Georgiev, D., Mahlknecht, P., Hyam, J., Foltynie, T., Limousin, P., De Vita, E., Jahanshahi, M., Hariz, M., Ashburner, J., Behrens, T., & Zrinzo, L. (2017). Subthalamic deep brain stimulation sweet spots and hyperdirect cortical connectivity in Parkinson’s disease. NeuroImage, 158, https://doi.org/10.1016/j.neuroimage.2017.07.012

Objectives
Firstly, to identify subthalamic region stimulation clusters that predict maximum improvement in rigidity, bradykinesia and tremor, or emergence of side-effects; and secondly, to map-out the cortical fingerprint, mediated by the hyperdire... Read More about Subthalamic deep brain stimulation sweet spots and hyperdirect cortical connectivity in Parkinson’s disease.

Imaging Pain Relief in Osteoarthritis (IPRO): protocol of a double-blind randomised controlled mechanistic study assessing pain relief and prediction of duloxetine treatment outcome (2017)
Journal Article
Reckziegel, D., Bailey, H., Cottam, W. J., Tench, C. R., Mahajan, R. P., Walsh, D. A., …Auer, D. P. (in press). Imaging Pain Relief in Osteoarthritis (IPRO): protocol of a double-blind randomised controlled mechanistic study assessing pain relief and prediction of duloxetine treatment outcome. BMJ Open, 7(6), Article e014013. https://doi.org/10.1136/bmjopen-2016-014013

Introduction: Osteoarthritis (OA) pain is a major cause of long-term disability and chronic pain in the adult population. One in five patients does not receive satisfactory pain relief, which reflects the complexity of chronic pain and the current la... Read More about Imaging Pain Relief in Osteoarthritis (IPRO): protocol of a double-blind randomised controlled mechanistic study assessing pain relief and prediction of duloxetine treatment outcome.

Limbic grey matter changes in early Parkinson's disease (2017)
Journal Article
Li, X., Xing, Y., Schwarz, S. T., & Auer, D. P. (in press). Limbic grey matter changes in early Parkinson's disease. Human Brain Mapping, https://doi.org/10.1002/hbm.23610

The purpose of this study was to investigate local and network related changes of limbic grey matter in early Parkinson’s disease (PD) and their interrelation with non-motor symptom severity. We applied voxel-based morphometric methods in 538 T1 MRI... Read More about Limbic grey matter changes in early Parkinson's disease.